$50 billion "shoe drops": French bank says Oracle Corporation's financing is a "risk clearing", target price $290
The announcement by Oracle Corporation regarding its 2026 equity and debt financing plan is a "risk clarification event" for this IT giant.
Investment bank BNP Paribas of France stated that the announcement by Oracle Corporation (ORCL.US) regarding its 2026 equity and debt financing plan is a "risk clarification event" for the IT giant. Analyst Stefan Slowinski of the bank has a target price of $290 for Oracle Corporation's stock.
Slowinski wrote in a report to clients, "We believe that Oracle Corporation's financing announcement could be a potential risk clarification event for its stock, especially when combined with the upcoming financing round for OpenAI (recent reports suggest a strong demand in the market for its financing in the range of $50 billion to $100 billion)."
"As the ability of Oracle Corporation to provide funding for its OCI (Oracle Cloud Infrastructure) construction and the ability of OpenAI to fulfill its funding obligations become clearer, we expect these issues to decrease in importance in investor discussions, allowing the market to refocus on whether Oracle Corporation can convert its large remaining performance obligations (RPO) into OCI revenue."
He added that using a financing structure involving both debt and equity (while limiting equity dilution) should help the company maintain its target investment-grade credit profile.
Slowinski also stated, "Furthermore, Oracle Corporation plans to raise $22.5 billion to $25 billion in debt through a single issue, which should alleviate concerns in the market about its repeated entrance into the financing market in calendar year 2026 (CY26) and may result in the company obtaining more favorable terms from credit investors."
Last week, Oracle Corporation announced that it expects to raise $45 billion to $50 billion in 2026 to expand additional capacity for its cloud infrastructure business. The company plans to meet its funding needs through a combination of debt and equity. On the equity side, Oracle Corporation anticipates that approximately half of its 2026 financing total will come from a combination of equity-linked instruments and common stock issuance.
Related Articles

Shenzhen Hongfuhan Technology (301086.SZ) signed a cooperation framework agreement with Guangdong Quanxiang and Jiangxi XieXun.
Mudanjiang Hengfeng Paper Co., Ltd. (600356.SH) plans to invest 349 million yuan in a new green printing project.

Chongqing Zhifei Biological Products (300122.SZ): The herpes zoster mRNA vaccine has been approved for clinical trials.
Shenzhen Hongfuhan Technology (301086.SZ) signed a cooperation framework agreement with Guangdong Quanxiang and Jiangxi XieXun.

Mudanjiang Hengfeng Paper Co., Ltd. (600356.SH) plans to invest 349 million yuan in a new green printing project.
Chongqing Zhifei Biological Products (300122.SZ): The herpes zoster mRNA vaccine has been approved for clinical trials.

RECOMMEND

Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026

Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026

2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026


